Dr Bonner serves as a scientific resource and technical advisor for both clients and internal teams in managing bioassays from development, to validation, to application. He received his PhD in Biochemistry from the University of Illinois (IL, USA) in 2001, and has expertise in a wide variety of fields including protein chemistry, molecular biology, microbiology, and immunology. He has expertise in validating PK and biomarker assays, both single-plex and multi-plex, across a variety of analytical platforms. Dr Bonner also has expertise in validation of antidrug antibody assays, with a particular focus on the application of statistical methods for cut-point determination.
Questions
1 Could you introduce yourself and explain what began your interest in immunogenicity? [Time – 00:30]
2 When investigating immunogenicity, what technologies do you use at Eurofins? [Time – 03:30]
3 What are the challenges you face when assessing immunogenicity? [Time – 04:30]
4 How does Eurofins’s portfolio of services help with these challenges? [Time – 06:38]
5 What are your top three tips for studying immunogenicity? [Time – 07:59]
6 Where do you hope this field will be in 5–10 years’ time? [Time – 11:10]
Dr Bonner serves as a scientific resource and technical advisor for both clients and internal teams in managing bioassays from development, to validation, to application. He received his PhD in Biochemistry from the University of Illinois (IL, USA) in 2001, and has expertise in a wide variety of fields including protein chemistry, molecular biology, microbiology, and immunology. He has expertise in validating PK and biomarker assays, both single-plex and multi-plex, across a variety of analytical platforms. Dr Bonner also has expertise in validation of antidrug antibody assays, with a particular focus on the application of statistical methods for cut-point determination.
